Treatment of ocular infections with topical antibacterials

被引:41
作者
Leeming, JP [1 ]
机构
[1] Bristol Royal Infirm & Gen Hosp, Publ Hlth Lab, Bristol BS2 8HW, Avon, England
关键词
D O I
10.2165/00003088-199937050-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Topically applied ophthalmic antibacterial preparations are widely used in the treatment of patients with superficial ocular infections. In addition, they are frequently used to augment treatment for intraocular infection administered systemically or via local instillation. Direct application delivers high concentrations of antimicrobial agents to the surface of the eye conveniently, quickly and with minimal systemic exposure to the agent. However, antibacterials are rapidly dissipated from the tear film and intraocular penetration of topical antibacterial agents is generally poor, necessitating intensive application for successful treatment of corneal infections. Therapeutic concentrations are rarely achieved at other sites in the eye. This article reviews what is known of the pharmacokinetics of topical ocular agents and how this information can be used to optimise ocular persistence and penetration and minimise systemic absorption of antibacterials. A review of the features of the most commonly employed topical antibacterials suggests that for the treatment of uncomplicated bacterial conjunctivitis there is little difference between the various agents in terms of clinical efficacy, although chloramphenicol should be used with care because of its potential haematological toxicity. Carefully considered therapy is imperative for bacterial keratitis; fortified beta-lactam/aminoglycoside combinations are often used for these infections. The fluoroquinolones appear promising, but caution is necessary in treating keratitis of unknown aetiology with these agents alone because of inherent and emerging acquired resistance among Gram-positive bacteria.
引用
收藏
页码:351 / 360
页数:10
相关论文
共 63 条
[1]  
*BACT KER STUD GRO, 1995, ARCH OPHTHALMOL-CHIC, V113, P1257
[2]   CONCENTRATION OF GENTAMICIN IN EXPERIMENTAL CORNEAL ULCERS - TOPICAL VS SUBCONJUNCTIVAL THERAPY [J].
BAUM, JL ;
BARZA, M ;
SHUSHAN, D ;
WEINSTEIN, L .
ARCHIVES OF OPHTHALMOLOGY, 1974, 92 (04) :315-317
[3]  
BEASLEY H, 1975, ARCH OPHTHALMOL-CHIC, V93, P184
[4]  
BENSON H, 1974, ARCH OPHTHALMOL-CHIC, V91, P313
[5]   A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones' [J].
Blondeau, JM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 :1-11
[6]  
BORRMANN L, 1992, CORNEA, V11, P226
[7]   Fluoroquinolones in the treatment of bacterial keratitis [J].
Bower, KS ;
Kowalski, RP ;
Gordon, YJ .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1996, 121 (06) :712-715
[8]   OFLOXACIN COMPARED WITH CHLORAMPHENICOL IN THE MANAGEMENT OF EXTERNAL OCULAR INFECTION [J].
BRON, AJ ;
LEBER, G ;
RIZK, SNM ;
BAIG, H ;
ELKINGTON, AR ;
KIRKBY, GR ;
NEOH, C ;
HARDEN, A ;
LEONG, T .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1991, 75 (11) :675-679
[9]   OCULAR PENETRATION OF TOPICALLY APPLIED NORFLOXACIN 0.3-PERCENT IN THE RABBITS AND IN HUMANS [J].
BRON, AM ;
PECHINOT, A ;
GARCHER, C ;
GUYONNET, G ;
KAZMIERCZAK, A .
JOURNAL OF OCULAR PHARMACOLOGY, 1992, 8 (03) :241-246
[10]   PHARMACOKINETIC CONSIDERATIONS IN THE TREATMENT OF BACTERIAL KERATITIS [J].
CALLEGAN, MC ;
OCALLAGHAN, RJ ;
HILL, JM .
CLINICAL PHARMACOKINETICS, 1994, 27 (02) :129-149